ADT deprives PCa cells of the stimulatory effects of androgen hormones, either by directly reducing circulating androgen levels, or via AR-signalling inhibitors (ARSi) that block the ability of the androgen receptor (AR) to bind its ligand, thereby attenuating AR-dependent tumour growth (Attar et al., 2009). Here, AR is linked to neoplasm.